Evaxion's Q2 2025 Financial Results and Business Update

Evaxion A/S, a clinical-stage TechBio company, announces its business update and second quarter 2025 financial results. Highlights include the completion of treatment for all patients in the phase 2 trial of its personalized cancer vaccine EVX-01, and the recruitment for the one-year extension of the trial. The company has also received a grant from the Gates Foundation to explore a new sub-unit vaccine against polio, and has expanded its R&D pipeline with EVX-B4, a new vaccine program against Group A Streptococcus bacteria. The search for a new CEO is ongoing following the stepping down of Christian Kanstrup.